Literature DB >> 217893

Antibody to varicella-zoster virus after passive immunization against chickenpox.

A A Gershon, S Piomelli, M Karpatkin, E Smithwick, S Steinberg.   

Abstract

Antibody titers to varicella-zoster virus were measured in varicella-susceptible immunocompromised children 48 h after they received either one of two lots of zoster immune globulin (ZIG) or a selected lot of immune serum globulin (ISG). Globulin was given to modify varicella in these children after exposure to varicella or zoster. Indirect immunofluorescence antibody titers (FAMA) of children after receipt of globulin ranged from less than 1:2 to 1:32. Geometric mean FAMA titers were highest after 1.2 ml of ISG per kg (FAMA titer 1:128) and 0.16 ml of ZIG lot A per kg (FAMA titer 1:1,024). Selected batches of ISG titering 1:128 or greater by FAMA, at a dose of 1.2 ml/kg, may be used to attempt to modify varicella in susceptible high-risk individuals when ZIG is not available.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 217893      PMCID: PMC275333          DOI: 10.1128/jcm.8.6.733-735.1978

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Modification of chicken pox in family contacts by administration of gamma globulin.

Authors:  A H ROSS
Journal:  N Engl J Med       Date:  1962-08-23       Impact factor: 91.245

2.  Detection of antibody to Varicella-Zoster virus by immune adherence hemagglutination.

Authors:  A A Gershon; Z G Kalter; S Steinberg; W J Kuhns
Journal:  Proc Soc Exp Biol Med       Date:  1976-04

3.  Antibody to varicella-zoster virus-induced membrane antigen: immunofluorescence assay using monodisperse glutaraldehyde-fixed target cells.

Authors:  J A Zaia; M N Oxman
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

4.  Determination of neutralizing antibody and IgG antibody to varicella-zoster virus and of IgG antibody to membrane antigens by the immunoperoxidase technique.

Authors:  G Gerna; G Achilli; R W Chambers
Journal:  J Infect Dis       Date:  1977-06       Impact factor: 5.226

5.  Zoster immune globulin. A further assessment.

Authors:  A A Gershon; S Steinberg; P A Brunell
Journal:  N Engl J Med       Date:  1974-01-31       Impact factor: 91.245

6.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

7.  Seroepidemiologic survey of varicella: Value of specific fluorescent antibody test.

Authors:  A A Gershon; S Krugman
Journal:  Pediatrics       Date:  1975-12       Impact factor: 7.124

  7 in total
  2 in total

1.  Varicella seroprevalence in the U.S.: data from the National Health and Nutrition Examination Survey, 1999-2004.

Authors:  Meredith A Reynolds; Deanna Kruszon-Moran; Aisha Jumaan; D Scott Schmid; Geraldine M McQuillan
Journal:  Public Health Rep       Date:  2010 Nov-Dec       Impact factor: 2.792

Review 2.  Impact of varicella vaccine on varicella-zoster virus dynamics.

Authors:  D Scott Schmid; Aisha O Jumaan
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.